Key Takeaways
- • Skybound Venture Capital secured a $38 million oversubscribed first close for its founder-led deeptech fund, anchored by the European Investment Fund, positioning it as a significant new player in European early-stage technology investing.
- • The Athens-based fund targets pre-seed and seed-stage companies across infrastructure, advanced computing, bioengineering, and frontier technologies, with initial cheques ranging from $500,000 to $2 million and substantial follow-on reserves retained for concentrated portfolio companies.
- • Co-founders Thaleia Misailidou (formerly Marathon Venture Capital) and George Varvarelis (co-founder of Augmenta, acquired by CNH Industrial) bring operational and founding experience to the fund's operationally focused investment strategy emphasizing defensible, technically complex technologies.
- • Skybound's first investment is in Neurosoft Bioelectronics, a company developing scalable, minimally invasive brain-computer interfaces, signaling focus on high-impact biotechnology infrastructure.
- • The fund explicitly positions itself against passive European venture capital models, prioritizing founder-led investment approaches and companies building hardware and software with long-term industrial and societal impact.
Summary
Skybound Venture Capital has launched a deeptech-focused venture fund with $38 million in capital secured at its first close, marking a new entrant in the European early-stage technology investment landscape. The oversubscribed round was anchored by the European Investment Fund, signaling institutional confidence in the fund's thesis and management team.
Based in Athens, Skybound was founded by Thaleia Misailidou, who previously held a position at Marathon Venture Capital and has established credibility within the Greek deeptech ecosystem, alongside George Varvarelis, a serial entrepreneur and co-founder of Augmenta, an agricultural technology company acquired by CNH Industrial. This combination of venture capital experience and operating founder background shapes the fund's stated approach: operationally intensive support for technically ambitious founders rather than passive capital provision.
The fund's investment scope spans pre-seed and seed-stage companies developing technically complex solutions across infrastructure, advanced computing, bioengineering, and frontier technologies. Skybound plans to deploy initial cheques between $500,000 and $2 million per investment while maintaining a concentrated portfolio strategy with significant reserves allocated for follow-on investments in selected companies. This structure reflects a commitment to deep engagement with portfolio companies rather than broad diversification.
Varvarelis articulated the fund's strategic positioning in commentary on launch, emphasizing that European venture capital requires investors with operational credibility and founder mentality rather than passive capital. The fund's inaugural investment in Neurosoft Bioelectronics—a company developing scalable, minimally invasive brain-computer interfaces—demonstrates focus on hardware-intensive deeptech with substantial technical complexity and long-term industrial applications, aligning with the fund's stated priority of backing founders building "atoms, not just bits."
Based in Athens, Skybound was founded by Thaleia Misailidou, who previously held a position at Marathon Venture Capital and has established credibility within the Greek deeptech ecosystem, alongside George Varvarelis, a serial entrepreneur and co-founder of Augmenta, an agricultural technology company acquired by CNH Industrial. This combination of venture capital experience and operating founder background shapes the fund's stated approach: operationally intensive support for technically ambitious founders rather than passive capital provision.
The fund's investment scope spans pre-seed and seed-stage companies developing technically complex solutions across infrastructure, advanced computing, bioengineering, and frontier technologies. Skybound plans to deploy initial cheques between $500,000 and $2 million per investment while maintaining a concentrated portfolio strategy with significant reserves allocated for follow-on investments in selected companies. This structure reflects a commitment to deep engagement with portfolio companies rather than broad diversification.
Varvarelis articulated the fund's strategic positioning in commentary on launch, emphasizing that European venture capital requires investors with operational credibility and founder mentality rather than passive capital. The fund's inaugural investment in Neurosoft Bioelectronics—a company developing scalable, minimally invasive brain-computer interfaces—demonstrates focus on hardware-intensive deeptech with substantial technical complexity and long-term industrial applications, aligning with the fund's stated priority of backing founders building "atoms, not just bits."
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.